Adding local treatments to standard therapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how adding local treatments (like targeted radiation or chemotherapy directly to the liver tumor) to your current immunotherapy and targeted therapy combination might affect outcomes for people with advanced liver cancer. It aims to find out which patients benefit most from adding these extra treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with liver cancer that cannot be surgically removed.
- You are already receiving a combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) as your first-line treatment, with the two medications started within 28 days of each other.
- You have at least one liver tumor that has not been treated with local therapy (such as embolization or radiation) and can be measured on a CT or MRI scan.
- You have not received any local therapy for your liver cancer in the past 60 days.
- You are generally able to perform daily activities with some help (ECOG score 0-2), and you have no serious bleeding problems or uncontrolled varices (enlarged veins in the esophagus or stomach).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination therapy for liver cancer that cannot be surgically removed. It uses an immune-boosting drug (atezolizumab), a drug that blocks blood flow to tumors (bevacizumab), and a type of chemotherapy that is delivered directly into the liver artery (HAIC). This combination may help shrink liver tumors and improve outcomes.
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial tests adding radiation (SBRT) to a combination of immunotherapy drugs (atezolizumab and bevacizumab) for people with liver cancer that has spread into the main portal vein. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.